These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 17558264)

  • 41. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
    Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW
    J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
    Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
    Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.
    Lemack GE
    Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351
    [No Abstract]   [Full Text] [Related]  

  • 45. Antimuscarinic drugs to treat overactive bladder.
    Robinson D; Cardozo L
    BMJ; 2012 Mar; 344():e2130. PubMed ID: 22453185
    [No Abstract]   [Full Text] [Related]  

  • 46. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract]   [Full Text] [Related]  

  • 51. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract]   [Full Text] [Related]  

  • 52. Overactive bladder: a better understanding of pathophysiology, diagnosis and management.
    Wein AJ; Rackley RR
    J Urol; 2006 Mar; 175(3 Pt 2):S5-10. PubMed ID: 16458739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overactive bladder.
    Carr LK
    Can J Urol; 2008 Aug; 15 Suppl 1():32-6; discussion 36. PubMed ID: 18700063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overactive bladder significantly affects quality of life.
    Abrams P; Kelleher CJ; Kerr LA; Rogers RG
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S580-90. PubMed ID: 11183901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology of urinary incontinence, voiding dysfunction, and overactive bladder.
    Rahn DD; Roshanravan SM
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):463-74. PubMed ID: 19932410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bladder sensation measures and overactive bladder.
    Rapp DE; Neil NJ; Govier FE; Kobashi KC
    J Urol; 2009 Sep; 182(3):1050-4. PubMed ID: 19616792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drug treatments for urinary incontinence.
    Robinson D; Cardozo L
    Maturitas; 2010 Apr; 65(4):340-7. PubMed ID: 20097022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.